Editorial

The Microbiome Revolution: New Insights for Personalized Medicine

Lucrezia Laterza * and Irene Mignini

CEMAD Digestive Diseases Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
* Correspondence: laterza.lucrezia@gmail.com

The availability of new culture-independent techniques to study microbes led to the explosion of the gut microbiota revolution in recent decades. Thanks to the information deriving from 16-RNA and metagenomics, we have begun to gain insight into a previously unexplored organ: the microbiome. Thus, we changed our ontological perspective of the human body, considering it as the result of the interaction between eukaryotic cells—the body as traditionally intended—and prokaryotic cells, consisting in the multiple microorganisms living in different body niches, which constitute the "mammalian holobiont" [1]. In fact, even if the gut microbiome is the first and most studied one, multiple microbiomes have been evaluated. Previously considered sterile districts have been questioned and new possible unexpected niches have been postulated. Beyond the biological interest, the knowledge on the microbiome offers a unique opportunity for personalized medicine as it constitutes the variable part of our genome, contributing to more than 90% of the variability among the individuals, whereas our traditionally intended genome shows a more than 90% identity among individuals [2]. Furthermore, beyond the mere characterization of microorganisms constituting the microbiome, thanks to proteomics and metabolomics, we can characterize the possible function that they have in physiologic and pathologic processes [3].

Considering these characteristics, the study of the microbiome will provide new opportunities to understand the pathogenesis of many non-communicable diseases, and it may be used for diagnosis, staging and tailoring different therapies on individual specific characteristics. Aiming at exploring the potential applications of microbiome in the personalization of medicine, we propose this Special Issue to collect new original data on the study of the microbiome and to offer the reader the main novelties in the landscape of the microbiome in the perspective of personalized medicine.

In such a context, the gut microbiome plays an undoubtedly pivotal role, not only in gastrointestinal but also extra-gastrointestinal disorders.

In gastrointestinal diseases, the contribution of the gut microbiota in the pathophysiology of both organic and functional disorders is now largely recognized. The review by Piccioni et al. underlined how dysbiosis, causing imbalance between pro-inflammatory and anti-inflammatory bacterial species, can trigger mucosal and peri-visceral inflammation leading to acute diverticulitis, and hypothesized a possible therapeutic role of probiotics in this setting, which is still to be confirmed by further evidence [4]. Grigor’eva et al. analysed fecal microbiota in patients affected by gallbladder stones and described how cholecystectomy can modify bacterial abundance [5]. Moreover, Barandouzi et al. showed that the microbiome composition was different in patients with irritable bowel syndrome and healthy controls and revealed the association between bacterial diversity and the consumption of specific foods such as caffeine, thus highlighting the interaction between microbiota and the environment [6]. This relationship has also been confirmed by data concerning non-gastrointestinal settings, as it is described in the study by Lin et al., which...
focused on a population of patients undergoing hemodialysis and analysed the impact of beta-blockers on the gut microbiome [7].

The potential link between the gut microbiome and apparently disconnected diseases has been investigated in multiple different contexts. Some districts, notably the urinary tract, can be more easily colonized by gut bacteria due to their intestinal contiguity. On this basis, our group examined how gut microbiome and intestinal barrier disruption can impact on the pathogenesis of urinary tract infections, particularly recurrent cystitis [8]. Nonetheless, the role of the gut microbiome is not limited to contiguous segments. As Cornejo-Pareja et al. showed in their pilot study about autoimmune-based thyroid diseases, gut microbiome alterations may contribute to the impairment of the immune system and subsequent onset of autoimmune disorders [9]. Furthermore, the pilot study by Chernevskaya et al. underlined the possible role of gut microbiota in identifying patients with a high risk of postoperative complications after cardiac surgery [10]. Similarly, Yamamura et al. demonstrated that the characteristics of lipid and energy metabolism of gut microbiota were able to predict a response to probiotic therapy in patients with schizophrenia [11].

However, the gut microbiome is not the unique target for diagnosis and therapy, and growing interest is rising around other microbiomes. In this context, it is worth noting that recent findings have also revealed the presence of bacterial species in some niches which were traditionally considered sterile, questioning an old paradigm and providing new potential therapeutic targets.

Indeed, Bellando-Randone et al. summarized current evidence about the contribution of oral microbiomes in the pathogenesis of different rheumatic diseases and propose to apply artificial intelligence, especially machine learning, to understand the link between oral microbiota and rheumatic diseases [12]. Chuang et al. observed that the tonsil microbiota composition was associated with chronic tonsillitis and oxygen desaturation in children affected by obstructive sleep apnea syndrome [13]. Moreover, in two different studies, Higuchi et al. evaluated the microbiome of two previously unexplored districts. They analysed in particular mesothelioma-specific [14] and thymoma-specific [15] microbiota, using resected or biopsied mesothelioma samples and resected thymoma samples, respectively, suggesting a possible microbial role in cancerogenesis. Similarly, based on emerging evidence that the uterus is not sterile, Boutriq et al. presented in their review the most recent data concerning the potential role of the endometrial microbiome in endometrial cancer and its possible interplay with the gut microbiome [16].

From diagnosis, research is now moving towards therapeutic objectives. Microbiome modulation through pre-biotics, pro-biotics and non-absorbable oral antibiotics (e.g., rifaximin) is an already a diffuse practice, especially but not only in gastrointestinal disorders, but further investigation is needed to identify more personalized treatments [17,18]. Di Leo et al. administered rifaximin to mice models for IgA nephropathy and observed symptom improvement, suggesting an unexplored therapeutic direction [19]. Fecal microbiota transplantation (FMT) usefulness in re-establishing intestinal eubiosis is widely recognized and recommended for specific indications, notably recurrent Clostridioides difficile colitis, but its role seems not to be limited to this setting, and it has been explored in multiple diseases, as Pession et al. showed in their review addressing the role of FMT in allogenic hematopoietic stem-cell recipients [20]. Not only Clostridioides infections, but also the treatment of gut graft-versus-host disease and prevention of gut dysbiosis or decolonization from antibiotic-resistant bacteria could be the main applications. Furthermore, in order to promote research and novel therapeutic strategies, Liang et al. developed a rabbit model of cystic fibrosis that, as well as cystic fibrosis human patients, was characterized by a dysbiotic microbiota compared to wild-type rabbits [21].

Giant steps have been made so far on microbiome investigation from the perspective of personalized medicine. However, certain aspects remain unclear. For example, as Basson et al. highlighted, poor study reproducibility is one of the current concerns [22]. They speculated on the possible causes of study irreproducibility and proposed some solutions, thus indicating lights and shadows on our current knowledge on this complex
and challenging topic that the microbiome represents. As this Special Issue pointed out, actual data are very promising, but research should keep on exploring the various unsolved issues to perfect the use of microbiome data for the personalization of medicine.

**Author Contributions:** Conceptualization, L.L.; writing—original draft preparation, L.L. and I.M.; writing—review and editing, L.L. and I.M.; supervision, L.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** L.L. is a consultant for Actial Farmaceutica. I.M. has no conflict to declare.

**References**

1. Zwart, H. “Love Is a Microbe Too”: Microbiome Dialectics. *Endeavour* 2022, 46, 100816. [CrossRef] [PubMed]
2. Adams, C.; Gutierrez, B. The Microbiome Has Multiple Influences on Human Health. *J. Microbiol. Biotechnol.* 2018, 7, 1–8.
3. Walker, M.E.; Simpson, J.B.; Redinbo, M.R. A Structural Metagenomics Pipeline for Examining the Gut Microbiome. *Curr. Opin. Struct. Biol.* 2022, 75, 102416. [CrossRef] [PubMed]
4. Piccioni, A.; Franza, L.; Brigida, M.; Zanza, C.; Torelli, E.; Petrucci, M.; Nicolò, R.; Covino, M.; Candelli, M.; Saviano, A.; et al. Gut Microbiota and Acute Diverticulitis: Role of Probiotics in Management of This Delicate Pathophysiological Balance. *J. Pers. Med.* 2021, 11, 298. [CrossRef]
5. Grigor’eva, I.; Romanova, T.; Naumova, N.; Alikina, T.; Kuznetsov, A.; Kabilov, M. Gut Microbiome in a Russian Cohort of Pre- and Post-Cholecystectomy Female Patients. *J. Pers. Med.* 2021, 11, 294. [CrossRef]
6. Barandouzi, Z.A.; Lee, J.; Maas, K.; Starkweather, A.R.; Cong, X.S. Altered Gut Microbiota in Irritable Bowel Syndrome and Its Association with Food Components. *J. Pers. Med.* 2021, 11, 35. [CrossRef]
7. Lin, Y.-T.; Lin, T.-Y.; Hung, S.-C.; Liu, P.-Y.; Hung, W.-C.; Tsai, W.-C.; Tsai, Y.-C.; Delicano, R.A.; Chuang, Y.-S.; Kuo, M.-C.; et al. Differences in the Microbial Composition of Hemodialysis Patients Treated with and without β-Blockers. *J. Pers. Med.* 2021, 11, 198. [CrossRef]
8. Graziani, C.; Laterza, L.; Talocco, C.; Pizzoferato, M.; Di Simone, N.; D’Ippolito, S.; Ricci, C.; Gervasoni, J.; Persichilli, S.; Del Chierico, F.; et al. Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study. *J. Pers. Med.* 2022, 12, 1005. [CrossRef]
9. Cornejo-Pareja, I.; Ruiz-Limón, P.; Gómez-Pérez, A.M.; Molina-Vega, M.; Moreno-Indias, I.; Tinañones, F.J. Differential Microbial Pattern Description in Subjects with Autoimmune-Based Thyroid Diseases: A Pilot Study. *J. Pers. Med.* 2020, 10, 192. [CrossRef]
10. Chernevskaya, E.; Zuev, E.; Odintsova, V.; Mglei, A.; Beloborodova, N. Gut Microbiota as Early Predictor of Infectious Complications before Cardiovascular: A Prospective Pilot Study. *J. Pers. Med.* 2021, 11, 1113. [CrossRef] [PubMed]
11. Yamamura, R.; Okubo, R.; Katsumata, N.; Odamaki, T.; Hashimoto, N.; Kusumi, I.; Xiao, J.; Matsuoka, Y. Lipid and Energy Metabolism of the Gut Microbiota Is Associated with the Response to Probiotic Bifidobacterium Breve Strain for Anxiety and Depressive Symptoms in Schizophrenia. *J. Pers. Med.* 2021, 11, 987. [CrossRef] [PubMed]
12. Bellando-Randone, S.; Russo, E.; Venerito, V.; Matucci-Cerinic, M.; Iannone, F.; Tangaro, S.; Amedei, A. Exploring the Oral Microbiome in Rheumatic Diseases, State of Art and Future Prospective in Personalized Medicine with an AI Approach. *J. Pers. Med.* 2021, 11, 625. [CrossRef] [PubMed]
13. Chuang, H.-H.; Hsu, J.-F.; Chuang, L.-P.; Chiou, C.-H.; Huang, Y.-Y.; Li, H.-Y.; Chen, N.-H.; Huang, Y.-S.; Chuang, C.-W.; Huang, C.-G.; et al. Different Associations between Tonsil Microbiome, Chronic Tonsillitis, and Intermittent Hypoxemia among Obstructive Sleep Apnea Children of Different Weight Status: A Pilot Case-Control Study. *J. Pers. Med.* 2021, 11, 486. [CrossRef]
14. Higuchi, R.; Goto, T.; Hirotsu, Y.; Otake, S.; Oyama, T.; Amemiiya, K.; Mochizuki, H.; Omata, M. Streptococcus Australis and Ralstonia Pickettii as Major Microbiota in Mesotheliomas. *J. Pers. Med.* 2021, 11, 297. [CrossRef] [PubMed]
15. Higuchi, R.; Goto, T.; Hirotsu, Y.; Otake, S.; Oyama, T.; Amemiiya, K.; Ohyama, H.; Mochizuki, H.; Omata, M. Sphenomonas and Phenyllobacterium as Major Microbiota in Thymic Epithelial Tumors. *J. Pers. Med.* 2021, 11, 1092. [CrossRef]
16. Boutriq, S.; González-González, A.; Plaza-Andrades, I.; Laborda-Illanes, A.; Sánchez-Alcoholado, L.; Peralta-Linero, J.; Domínguez-Reco, M.E.; Bermejo-Perez, M.J.; Lavado-Valenzuela, R.; Alba, E.; et al. Gut and Endometrial Microbiome Dysbiosis: A New Emergent Risk Factor for Endometrial Cancer. *J. Pers. Med.* 2021, 11, 659. [CrossRef]
17. Ford, A.C.; Harris, L.A.; Lacy, B.E.; Quigley, E.M.M.; Moayyedi, P. Systematic Review with Meta-Analysis: The Efficacy of Probiotics, Prebiotics, Synbiotics and Antibiotics in Irritable Bowel Syndrome. *Aliment. Pharm.* 2018, 48, 1044–1060. [CrossRef]
18. Bloom, P.P.; Tapper, E.B.; Young, V.B.; Lok, A.S. Microbiome Therapeutics for Hepatic Encephalopathy. *J. Hepatol.* 2021, 75, 1452–1464. [CrossRef]
19. Di Leo, V.; Gleeson, P.J.; Sallustio, F.; Bounaix, C.; Da Silva, J.; Loreto, G.; Ben Mkaddem, S.; Monteiro, R.C. Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model. *J. Pers. Med.* **2021**, *11*, 309. [CrossRef]

20. Pession, A.; Zama, D.; Muratore, E.; Leardini, D.; Gori, D.; Guaraldi, F.; Prete, A.; Turrioni, S.; Brigidi, P.; Masetti, R. Fecal Microbiota Transplantation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review. *J. Pers. Med.* **2021**, *11*, 100. [CrossRef]

21. Liang, X.; Bouhamdan, M.; Hou, X.; Zhang, K.; Song, J.; Hao, K.; Jin, J.-P.; Zhang, Z.; Xu, J. Intestinal Dysbiosis in Young Cystic Fibrosis Rabbits. *J. Pers. Med.* **2021**, *11*, 132. [CrossRef] [PubMed]

22. Basson, A.R.; Cominelli, F.; Rodriguez-Palacios, A. ‘Statistical Irreproducibility’ Does Not Improve with Larger Sample Size: How to Quantify and Address Disease Data Multimodality in Human and Animal Research. *J. Pers. Med.* **2021**, *11*, 234. [CrossRef] [PubMed]